A melanocyte lineage program confers resistance to MAP kinase pathway inhibition

作者：Johannessen Cory M; Johnson Laura A; Piccioni Federica; Townes Aisha; Frederick Dennie T; Donahue Melanie K; Narayan Rajiv; Flaherty Keith T; Wargo Jennifer A; Root David E; Garraway Levi A^*

来源：Nature, 2013, 504(7478): 138-+.

DOI：10.1038/nature12688

Malignant melanomas harbouring point mutations (Val600Glu) in the serine/threonine-protein kinase BRAF (BRAF(V600E)) depend on RAF-MEK-ERK signalling for tumour cell growth(1). RAF and MEK inhibitors show remarkable clinical efficacy in BRAF(V600E) melanoma(2,3); however, resistance to these agents remains a formidable challenge(2,4). Global characterization of resistance mechanisms may inform the development of more effective therapeutic combinations. Here we carried out systematic gain-of-function resistance studies by expressing more than 15,500 genes individually in a BRAF(V600E) melanoma cell line treated with RAF, MEK, ERK or combined RAF-MEK inhibitors. These studies revealed a cyclic-AMP-dependent melanocytic signalling network not previously associated with drug resistance, including G-protein-coupled receptors, adenyl cyclase, protein kinase A and cAMP response element binding protein(CREB). Preliminary analysis of biopsies from BRAF (V600E) melanoma patients revealed that phosphorylated (active) CREB was suppressed by RAF-MEK inhibition but restored in relapsing tumours. Expression of transcription factors activated downstream of MAP kinase and cAMP pathways also conferred resistance, including c-FOS, NR4A1, NR4A2 and MITF. Combined treatment with MAPK-pathway and histone-deacetylase inhibitors suppressed MITF expression and cAMP-mediated resistance. Collectively, these data suggest that oncogenic dysregulation of a melanocyte lineage dependency can cause resistance to RAF-MEK-ERK inhibition, which may be overcome by combining signalling-and chromatin-directed therapeutics.

• 出版日期2013-12-5